Here’s what you should know:
1. The proceeds of the offering will redeem the 2.65 percent notes that were due October 2016. Boston Scientific had approximately $600 million in aggregate principal outstanding on the notes as of Feb. 26.
2. The company needs to repay short-term debt and related fees, expenses and premiums.
3. Once paid, Boston Scientific will provide redemption notices to trustees.
More articles on supply chain:
CMS made $36B in improper payments in FY2017 — 6 key notes
18 statistics on changes in ASC payer rates, supply costs, staff raises & expenses
Indianapolis pain practice looks to expand Midwest presence with private equity investment
